Kazia Therapeutics Moves Forward with Clinical Trials for Paxalisib Targeting Rare Epilepsy Disorders

Kazia Therapeutics Advances Paxalisib Trials

Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology firm specializing in oncology, has recently declared a notable progression in its clinical endeavors. The company's collaboration with Sovargen Co., Ltd., dedicated to refining treatments for central nervous system (CNS) conditions, has reached a pivotal moment. Sovargen has successfully dosed the initial patient in a Phase 1b/2a trial assessing Paxalisib, which aims to address intractable epilepsy linked to focal cortical dysplasia type 2 (FCD T2) and tuberous sclerosis complex (TSC). This milestone also activates a $2 million payment to Kazia as part of their licensing agreement.

This partnership commenced in March 2024, empowering Sovargen with the responsibility for the development, manufacturing, and global commercialization of Paxalisib for mTORopathy-related epilepsy, excluding specified regions in Asia. Additional future milestone payments could total up to $17 million, along with potential earnings from sub-licensing and royalties on product sales, illustrating Kazia’s strategic positioning within the biotech sector.

FCD T2 and TSC are rare genetic epilepsy disorders characterized by mutated genes leading to the overactivation of the mTOR pathway, resulting in resistant seizures. Currently, there are no approved treatments for FCD T2. Paxalisib stands out as an oral formulation, simultaneously inhibiting the PI3K and mTOR pathways, thereby anticipating a new approach to a challenging medical landscape.

CEO of Kazia, Dr. John Friend II, commented on the achievement, emphasizing the importance of exploring Paxalisib’s efficacy beyond oncology. He expressed optimism about the potential patient benefits as well as the ongoing commitment to cancer treatments.

In parallel, Cheolwon Park, CEO of Sovargen, highlighted the desperate need for effective therapies for families contending with FCD T2 and TSC. He reiterated the significance of this clinical trial milestone, demonstrating the dedication of both their investigative teams and the urgency in addressing these critical healthcare needs.

Kazia Therapeutics, based in Sydney, Australia, focuses not only on Paxalisib’s development in CNS disorders but also seeks to cultivate therapies for various cancer forms. With over 15 ongoing clinical studies, Paxalisib has already gained attention for its promising results in malignancies such as glioblastoma and breast cancer, along with several other cancers. Evidence of its potential led to the U.S. Food and Drug Administration (FDA) granting orphan drug status, acknowledging the high unmet need in these fields, further elevating Kazia's profile in the pharmacological arena.

In addition to Paxalisib, Kazia is undertaking the charge on other innovative therapeutic avenues. The EVT801 program targets VEGFR3, while the NDL2 initiative presents a promising approach to immunotherapy resistance. These projects represent Kazia’s commitment to tackling multifaceted challenges within the biomedical landscape.

As the clinical trials progress, stakeholders will observe the data generated to better ascertain Paxalisib's potential in treating rare neurological disorders, aiming ultimately to transform the treatment landscape for patients suffering from FCD T2 and TSC. Kazia's trajectory is a clear indicator of its vision and resilience in advancing complex medical treatments through innovative research.